Factory Direct Antibotic Dalbavancin Powder CAS171500-79-1

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: TGY201904170803
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Solid
• Purity: >99%
• Product Name: Dalbavancin
• Appearance: White Powder
• MOQ: 1kg
• CAS Number: 171500-79-1
• Delivery: EMS TNT
• Shelf Life: 24 Months
• Einecs: 206-141-6
• Transport Package: Foil Bag, Drum
• Specification: 99%
• Trademark: TGY
• Origin: China
• HS Code: 2200
• Production Capacity: 65 Kilogram/Kilograms Per Month More

Product Description

Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available.
Puhopharma specializes in controling the quality and reducing the impurities of Dalbavancin.
Our Dalbavancin is with the best quality and the most competitive price in China.
Dalbavancin (INN, trade names Dalvance in the US and Xydalba in Europe) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available.
It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).
It is a once-weekly, two-dose antibiotic, the rights to which Actavis acquired when it bought Durata Therapeutics in 2014.
The Food and Drug Administration approved dalbavancin in May 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria such as Staphylococcus aureus including methicillin-susceptible and methicillin-resistant strains of Streptococcus pyogenes, in intravenous dosage form.

Dalbavancin is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus(MRSA).
It has strong activity against many Gram-positive bacteria, including methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus,Streptococcus intermedius, and Streptococcus constellatus.
Dalbavancin is a semi-synthetic glycopeptide prepared from A40926 by introducing a positively charged lipophilic moiety in a previously unexplored region of the natural glycopeptide. This modification provides a longer in vivo half life, and improved in vitro activity against a variety of Gram positive and multi-drug resistant isolates such as MRSA and MRSE.